Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Anika Therapeutics

This article was originally published in The Gray Sheet

Executive Summary

Clinical trials for the Incert chemically cross-linked form of hyaluronic acid are expected to begin in 1999, the company says. Incert, which is intended to act as a barrier and reduce post-operative adhesions after pelvic or abdominal surgery, also holds potential for prevention of adhesions following gynecological and general surgery, Anika maintains
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT010489

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel